Mon Sep 09 15:17:23 UTC 2024: ## Immunovant’s Batoclimab Shows Promise in Treating Graves’ Disease, Guggenheim Reaffirms Buy Rating
**New York, NY** – Immunovant (NASDAQ:IMVT), a biopharmaceutical company focused on developing therapies for autoimmune diseases, continues to see positive momentum with its lead drug candidate, batoclimab. Following promising Phase II trial results for the treatment of Graves’ disease, Guggenheim has reaffirmed its Buy rating and $44.00 price target for the company.
The Phase II open-label trial, which included 25 participants, demonstrated that batoclimab, a subcutaneous injection, achieved a significant 68% success rate in normalizing thyroid hormone levels without increasing antithyroid drug (ATD) usage after 24 weeks. Notably, a 76% response rate was observed at week 12, even before the dosage was halved.
While the ATD-free rate declined from 56% at week 12 to 36% at week 24, the trial’s findings are considered crucial, as the upcoming pivotal trial will measure the percentage of patients who can discontinue ATD usage.
Immunovant’s management has announced that the first of two Phase III trials for batoclimab is scheduled to begin by the end of 2024. With a planned enrollment of 240 patients, the trial is expected to be adequately powered to detect a significant difference in the primary endpoint.
The favorable safety profile of batoclimab, with no new safety concerns emerging during the trial, further bolsters the drug’s potential. Guggenheim believes Graves’ disease presents a substantial commercial opportunity for Immunovant based on the trial results and the company’s epidemiological studies.
Other analysts, including Oppenheimer, Stifel, and Piper Sandler, have also expressed positive views on Immunovant following the positive trial data.
While recent financial metrics indicate a positive investor sentiment and strong price momentum, analysts have revised their earnings expectations downwards for the upcoming period, signaling potential concerns about future profitability.
Investors are advised to weigh the potential risks and rewards associated with Immunovant’s stock based on the clinical trial results, financial performance, and future outlook. For a comprehensive analysis, visit https://www.investing.com/pro/IMVT.
First Piper 